CY1116011T1 - Hla-a*1101-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση που το περιλαμβανει - Google Patents
Hla-a*1101-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση που το περιλαμβανειInfo
- Publication number
- CY1116011T1 CY1116011T1 CY20151100113T CY151100113T CY1116011T1 CY 1116011 T1 CY1116011 T1 CY 1116011T1 CY 20151100113 T CY20151100113 T CY 20151100113T CY 151100113 T CY151100113 T CY 151100113T CY 1116011 T1 CY1116011 T1 CY 1116011T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hla
- peptide
- pharmaceutical composition
- ability
- pipe
- Prior art date
Links
- 108010075704 HLA-A Antigens Proteins 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000011786 HLA-A Antigens Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 abstract 3
- 102000040856 WT1 Human genes 0.000 abstract 2
- 108700020467 WT1 Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
- A61K40/4243—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με ΗLΑ-Α*1101-περιορισμένο WT1 πεπτίδιο, πιο συγκεκριμένα με πεπτίδιο που περιλαμβάνει αμινοξική αλληλουχία αποτελούμενη από 9 διαδοχικά αμινοξέα από πρωτεΐνη WT1, όπου το πεπτίδιο έχει την ικανότητα να δεσμεύεται σε ΗLΑ-Α*1011 μόριο, και επίσης έχει την ικανότητα να επάγει CTL. Η παρούσα εφεύρεση επίσης σχετίζεται με πεπτιδοδιμερές που έχει την ικανότητα να δεσμεύεται σε ΗLΑ-Α*1011 μόριο και που έχει την ικανότητα να επάγει CTL, στο οποίο δύο πεπτιδομονομερή -με έκαστο να περιλαμβάνει αμινοξική αλληλουχία αποτελούμενη από 9 διαδοχικά αμινοξέα από πρωτεΐνη WT1 και να περιλαμβάνει τουλάχιστον ένα κατάλοιπο κυστεΐνης- είναι ενωμένα μεταξύ τους μέσω δισουλφιδικού δεσμού. Περαιτέρω, η παρούσα εφεύρεση σχετίζεται με πολυνουκλεοτίδιο που κωδικεύει το πεπτίδιο, με φαρμακευτική σύνθεση για τη θεραπευτική αγωγή και/ή πρόληψη καρκίνου που περιλαμβάνει το πεπτίδιο και τα όμοια.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006355356 | 2006-12-28 | ||
| EP10191234.3A EP2341142B8 (en) | 2006-12-28 | 2007-12-14 | HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116011T1 true CY1116011T1 (el) | 2017-01-25 |
Family
ID=39588385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100113T CY1116011T1 (el) | 2006-12-28 | 2015-02-04 | Hla-a*1101-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση που το περιλαμβανει |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US8653038B2 (el) |
| EP (6) | EP3026115B1 (el) |
| JP (1) | JP5484734B2 (el) |
| KR (1) | KR101525261B1 (el) |
| CN (5) | CN102335439B (el) |
| AR (1) | AR064555A1 (el) |
| AU (1) | AU2007340679B2 (el) |
| BR (1) | BRPI0720988A2 (el) |
| CA (5) | CA2886621A1 (el) |
| CY (1) | CY1116011T1 (el) |
| DK (3) | DK2479275T3 (el) |
| ES (4) | ES2556831T3 (el) |
| IL (4) | IL199052A0 (el) |
| MX (1) | MX2009007008A (el) |
| MY (1) | MY161664A (el) |
| NO (1) | NO20092774L (el) |
| NZ (4) | NZ577443A (el) |
| PH (1) | PH12014500902B1 (el) |
| PL (1) | PL2341142T3 (el) |
| PT (1) | PT2341142E (el) |
| RU (1) | RU2481398C2 (el) |
| SG (1) | SG177222A1 (el) |
| SI (1) | SI2341142T1 (el) |
| TW (3) | TWI417103B (el) |
| UA (1) | UA103154C2 (el) |
| WO (1) | WO2008081701A1 (el) |
| ZA (1) | ZA200903633B (el) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130062368A (ko) | 2003-11-05 | 2013-06-12 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드 |
| CA2900087C (en) | 2005-10-17 | 2024-02-13 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| PL2010209T3 (pl) | 2006-04-10 | 2017-04-28 | Sloan Kettering Inst For Cancer Res | Immunogeniczne peptydy WT-1 i sposoby ich użycia |
| BRPI0808084A2 (pt) | 2007-02-27 | 2014-07-22 | Int Inst Cancer Immunology Inc | Método para ativação de células t auxiliadoras e composição para uso no método. |
| WO2012046730A1 (ja) * | 2010-10-05 | 2012-04-12 | 国立大学法人大阪大学 | ヘルパーｔ細胞の活性化方法 |
| AU2012236068A1 (en) * | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| RU2633068C2 (ru) * | 2011-09-14 | 2017-10-11 | Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. | Способ измерения антитела против wt1 |
| HK1204261A1 (en) | 2012-01-13 | 2015-11-13 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| WO2014042226A1 (ja) | 2012-09-12 | 2014-03-20 | 株式会社癌免疫研究所 | 抗原特異的ヘルパーｔ細胞レセプター遺伝子 |
| SG11201504558TA (en) | 2012-12-11 | 2015-07-30 | Einstein Coll Med | Methods for high throughput receptor:ligand identification |
| NZ708990A (en) | 2012-12-17 | 2020-03-27 | Int Inst Cancer Immunology Inc | Method for activating helper t cell |
| ES2832546T3 (es) | 2013-01-15 | 2021-06-10 | Memorial Sloan Kettering Cancer Center | Péptidos WT-1 inmunogénicos y métodos de uso de los mismos |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| CN103961699B (zh) | 2013-02-05 | 2018-11-06 | 日东电工株式会社 | 经皮给予用wt1肽癌症疫苗组合物 |
| RU2014102945A (ru) | 2013-02-05 | 2015-08-10 | Нитто Денко Корпорейшн | Вакцинная композиция |
| RU2687026C2 (ru) | 2013-02-05 | 2019-05-06 | Нитто Денко Корпорейшн | Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения |
| KR20140099828A (ko) | 2013-02-05 | 2014-08-13 | 닛토덴코 가부시키가이샤 | 점막 투여용 백신 조성물 |
| CA2840937A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Vaccine composition for transdermal administration |
| RU2687144C2 (ru) | 2013-02-05 | 2019-05-07 | Нитто Денко Корпорейшн | Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения |
| JP2014169280A (ja) | 2013-02-05 | 2014-09-18 | Nitto Denko Corp | 経皮または粘膜投与用ワクチン組成物 |
| US10195258B2 (en) | 2013-02-05 | 2019-02-05 | Nitto Denko Corporation | Tape preparation of WT1 peptide cancer vaccine for transdermal administration |
| US10588952B2 (en) | 2013-03-29 | 2020-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate vaccine using trimming function of ERAP1 |
| JP5885885B2 (ja) | 2013-03-29 | 2016-03-16 | 大日本住友製薬株式会社 | Ｗｔ１抗原ペプチドコンジュゲートワクチン |
| KR102797324B1 (ko) | 2014-12-11 | 2025-04-22 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 혈관 신생병의 면역 요법 |
| AU2017266905B2 (en) | 2016-05-18 | 2022-12-15 | Albert Einstein College Of Medicine, Inc. | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
| JP7071288B2 (ja) | 2016-05-18 | 2022-05-18 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| KR102760578B1 (ko) | 2016-12-22 | 2025-02-03 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
| EP4431109A3 (en) | 2017-03-15 | 2024-11-27 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| WO2019131722A1 (ja) * | 2017-12-27 | 2019-07-04 | 大日本住友製薬株式会社 | Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物 |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2019189885A1 (ja) | 2018-03-29 | 2019-10-03 | ローム株式会社 | 半導体装置 |
| CN115867303A (zh) * | 2020-05-12 | 2023-03-28 | 住友制药株式会社 | 用于治疗癌症的药物组合物 |
| JP2023526723A (ja) | 2020-05-12 | 2023-06-23 | キュー バイオファーマ， インコーポレイテッド | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4575374A (en) * | 1983-02-16 | 1986-03-11 | Anis Aziz Y | Flexible anterior chamber lens |
| US5763209A (en) * | 1988-09-26 | 1998-06-09 | Arch Development Corporation | Methods and materials relating to the functional domains of DNA binding proteins |
| US5584304A (en) * | 1993-11-18 | 1996-12-17 | Allergan, Inc. | Method of inserting an IOL using a forceps inside a folding tube |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5984962A (en) * | 1996-01-22 | 1999-11-16 | Quantum Vision, Inc. | Adjustable intraocular lens |
| US6207375B1 (en) * | 1996-12-11 | 2001-03-27 | Mayo Foundation For Medical Educational & Research | TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer |
| US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7115272B1 (en) * | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7144581B2 (en) * | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7901693B2 (en) * | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7655249B2 (en) * | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20030039635A1 (en) * | 1998-09-30 | 2003-02-27 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20030072767A1 (en) * | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
| MY139226A (en) * | 1998-09-30 | 2009-08-28 | Corixa Corp | Compositions and methods for wt1 specific immunotherapy |
| US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| PL354348A1 (en) * | 1999-04-02 | 2004-01-12 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| WO2001025273A2 (en) * | 1999-10-04 | 2001-04-12 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
| US20030082194A1 (en) * | 2000-02-22 | 2003-05-01 | Alexander Gaiger | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| EP1261711A2 (en) * | 2000-02-22 | 2002-12-04 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| DE60224508T2 (de) * | 2001-03-22 | 2008-12-24 | International Institute of Cancer Immunology, Inc., Suita-shi | Wti-modifiziertes peptid |
| IL145015A0 (en) * | 2001-08-21 | 2002-06-30 | Nun Yehoshua Ben | Accommodating lens |
| US7553494B2 (en) * | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
| ATE466084T1 (de) * | 2002-06-12 | 2010-05-15 | Int Inst Cancer Immunology Inc | Hla-a24-restringiertes krebsantigenpeptid |
| CA2487489C (en) * | 2002-06-14 | 2010-11-23 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| SE0201863D0 (en) * | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| KR101399678B1 (ko) | 2003-01-15 | 2014-05-27 | 추가이 세이야쿠 가부시키가이샤 | 이량체화 펩티드 |
| US7976520B2 (en) * | 2004-01-12 | 2011-07-12 | Nulens Ltd. | Eye wall anchored fixtures |
| PT1731605E (pt) | 2004-03-31 | 2010-04-14 | Int Inst Cancer Immunology Inc | Péptidos antigénicos de cancro derivados de wt1 |
| JP2006045287A (ja) | 2004-08-02 | 2006-02-16 | Inax Corp | 弾性接着剤及びタイル張り壁面 |
| JP4719876B2 (ja) * | 2005-04-04 | 2011-07-06 | 国立大学法人愛媛大学 | Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
-
2007
- 2007-12-14 NZ NZ577443A patent/NZ577443A/en not_active IP Right Cessation
- 2007-12-14 DK DK12164855.4T patent/DK2479275T3/en active
- 2007-12-14 PT PT101912343T patent/PT2341142E/pt unknown
- 2007-12-14 UA UAA200907944A patent/UA103154C2/uk unknown
- 2007-12-14 CN CN201110235501.4A patent/CN102335439B/zh active Active
- 2007-12-14 DK DK10191234.3T patent/DK2341142T3/en active
- 2007-12-14 EP EP15201329.8A patent/EP3026115B1/en not_active Not-in-force
- 2007-12-14 EP EP12164855.4A patent/EP2479275B1/en not_active Not-in-force
- 2007-12-14 CN CN201210153918.0A patent/CN102659924B/zh active Active
- 2007-12-14 EP EP10191234.3A patent/EP2341142B8/en not_active Not-in-force
- 2007-12-14 SI SI200731565T patent/SI2341142T1/sl unknown
- 2007-12-14 CN CN201110235503.3A patent/CN102302788B/zh active Active
- 2007-12-14 KR KR1020097013472A patent/KR101525261B1/ko active Active
- 2007-12-14 CN CN2007800487491A patent/CN101573448B/zh active Active
- 2007-12-14 WO PCT/JP2007/074146 patent/WO2008081701A1/ja active Application Filing
- 2007-12-14 NZ NZ592510A patent/NZ592510A/xx not_active IP Right Cessation
- 2007-12-14 NZ NZ592509A patent/NZ592509A/xx not_active IP Right Cessation
- 2007-12-14 AU AU2007340679A patent/AU2007340679B2/en not_active Ceased
- 2007-12-14 ES ES12164856.2T patent/ES2556831T3/es active Active
- 2007-12-14 CA CA 2886621 patent/CA2886621A1/en not_active Abandoned
- 2007-12-14 CN CN2011102355279A patent/CN102295682A/zh active Pending
- 2007-12-14 ES ES10191234.3T patent/ES2526425T3/es active Active
- 2007-12-14 CA CA 2886619 patent/CA2886619A1/en not_active Abandoned
- 2007-12-14 CA CA002670658A patent/CA2670658A1/en active Pending
- 2007-12-14 NZ NZ601175A patent/NZ601175A/xx not_active IP Right Cessation
- 2007-12-14 EP EP07850650A patent/EP2098595A4/en not_active Withdrawn
- 2007-12-14 BR BRPI0720988-6A patent/BRPI0720988A2/pt active Search and Examination
- 2007-12-14 CA CA2886622A patent/CA2886622A1/en not_active Abandoned
- 2007-12-14 MX MX2009007008A patent/MX2009007008A/es active IP Right Grant
- 2007-12-14 ES ES15201329.8T patent/ES2629578T3/es active Active
- 2007-12-14 PL PL10191234T patent/PL2341142T3/pl unknown
- 2007-12-14 MY MYPI20092279A patent/MY161664A/en unknown
- 2007-12-14 ES ES12164855.4T patent/ES2554775T3/es active Active
- 2007-12-14 RU RU2009128979/10A patent/RU2481398C2/ru not_active IP Right Cessation
- 2007-12-14 CA CA 2886620 patent/CA2886620A1/en not_active Abandoned
- 2007-12-14 EP EP12164856.2A patent/EP2479276B1/en not_active Not-in-force
- 2007-12-14 US US12/521,533 patent/US8653038B2/en not_active Expired - Fee Related
- 2007-12-14 SG SG2011094588A patent/SG177222A1/en unknown
- 2007-12-14 DK DK12164856.2T patent/DK2479276T3/en active
- 2007-12-14 EP EP15181734.3A patent/EP2980219B1/en not_active Not-in-force
- 2007-12-14 JP JP2008552080A patent/JP5484734B2/ja active Active
- 2007-12-25 TW TW096149840A patent/TWI417103B/zh active
- 2007-12-25 TW TW105115481A patent/TWI599367B/zh active
- 2007-12-25 TW TW102124491A patent/TWI554280B/zh active
- 2007-12-27 AR ARP070105924A patent/AR064555A1/es unknown
-
2009
- 2009-05-26 ZA ZA2009/03633A patent/ZA200903633B/en unknown
- 2009-06-01 IL IL199052A patent/IL199052A0/en unknown
- 2009-07-27 NO NO20092774A patent/NO20092774L/no not_active Application Discontinuation
-
2011
- 2011-09-22 IL IL215332A patent/IL215332A0/en unknown
- 2011-09-22 IL IL215333A patent/IL215333A0/en unknown
- 2011-09-22 IL IL215334A patent/IL215334A0/en unknown
-
2013
- 2013-12-26 US US14/140,698 patent/US9272026B2/en active Active
-
2014
- 2014-04-24 PH PH12014500902A patent/PH12014500902B1/en unknown
-
2015
- 2015-02-04 CY CY20151100113T patent/CY1116011T1/el unknown
-
2016
- 2016-01-22 US US15/003,882 patent/US20160199472A1/en not_active Abandoned
-
2017
- 2017-10-27 US US15/796,368 patent/US20180064795A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116011T1 (el) | Hla-a*1101-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση που το περιλαμβανει | |
| CY1122691T1 (el) | Πρωτεϊνες δεσμευσης αλβουμινης ορου | |
| CY1121632T1 (el) | Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης | |
| CY1119265T1 (el) | Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου | |
| CY1121687T1 (el) | Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων | |
| CY1120137T1 (el) | Ενεσιμα σκευασματα βοτουλινικης τοξινης | |
| AR076349A1 (es) | Peptido auxiliar del antigeno del cancer | |
| CY1119219T1 (el) | Anti-ceacam5 αντισωματα και χρησεις αυτων | |
| CO2018000303A2 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
| CY1117351T1 (el) | Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης | |
| UA103882C2 (uk) | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина | |
| CY1115140T1 (el) | Πεπτιδια και η χρηση τους | |
| HRP20220214T1 (hr) | Imunomodulacijska sredstva | |
| CY1116264T1 (el) | Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2 | |
| WO2008118017A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
| BRPI0606687A2 (pt) | composições nutracêuticas | |
| CY1123997T1 (el) | Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου | |
| HRP20110240T1 (en) | Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine | |
| CY1119737T1 (el) | Νεες συνθεσεις και μεθοδοι | |
| UA118167C2 (uk) | Пептид та його застосування | |
| DK2231860T3 (da) | Polypeptid afledt protein A og i stand til at binde PDGF | |
| EA201200515A1 (ru) | Полипептиды и их применение | |
| EA201270313A1 (ru) | Композиции, которые индуцируют хелперное действие т-клеток | |
| PE20120170A1 (es) | Variantes de union a anti-albumina de suero mejoradas | |
| CY1120436T1 (el) | Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου |